The abstract is read at the publisher; the summary is JClub's.
Orally delivered metabolically engineered Escherichia coli EcN-HlpA-CGL (EHC) suppresses orthotopic colorectal cancer tumor growth and inhibits metastatic progression.
- Why it matters: Colorectal cancer has low tumor immunogenicity and an immunosuppressive tumor microenvironment, limiting the effectiveness of immunotherapy.
- What they did: The study uses an oral engineered bacterial platform expressing cystathionine γ-lyase to disrupt redox balance, trigger ferroptosis, and enhance immunogenic cell death, with immune profiling after administration.
- The result: In vivo, EHC induces robust systemic and gut mucosal immune activation, supporting a safe, effective immunotherapeutic strategy tailored to colorectal cancer.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.